Peter Pastore

Same pattern, fresh evidence. On April 27, ImmunityBio quietly expanded ResQ201A-NSCLC (NCT06745908) from a 2-arm trial to a 2-cohort, 4-arm trial. What changed: Original design: ANKTIVA + tislelizumab (BeiGene's CPI) + docetaxel vs docetaxel alone. New: adds Cohort B - ANKTIVA + the patient's prior failed CPI + docetaxel vs docetaxel alone. Each cohort randomized 2:1. Why it matters: Most US 2nd-line NSCLC patients failed Keytruda or Opdivo, not tislelizumab. The original Cohort A only worked for patients willing to switch CPIs. Cohort B captures the actual US patient population - and the actual ANKTIVA thesis, which is that IL-15 reactivates exhausted T cells regardless of which PD-1 or PD-L1 drug stopped working. This is also the design that maps to the Saudi label, which approved ANKTIVA for "2nd line lung cancer who relapsed following standard of care." Posted silently to ClinicalTrials.gov. A Stocktwits reader this morning: "good or bad? don't know." Both NCT07551544 and this update hit ClinicalTrials.gov on the same day, April 27. Two silent posts. Both read as worry by casual observers. Both are structural strengthening. Companies don't expand the design of trials they expect to fail.

Humacyte® has received a minimum $1.475M purchase commitment for our Symvess® acellular tissue–engineered vessel-tyod to support a clinical evaluation and outreach program in the Kingdom of Saudi Arabia. This program will help expand awareness of Symvess among healthcare providers across KSA as we continue discussions on establishing a joint venture and commercialization license in the region. This is another important step in our global expansion efforts and we look forward to supporting medical teams as they evaluate the potential of Symvess to improve patient care. For more details read the full press release here: 🔗 bit.ly/3PGVQiZ #Humacyte #Symvess #Biotechnology #GlobalHealth #TissueEngineering #RegenerativeMedicine #MedicalInnovation #ATEV #Innovation PLEASE SEE IMPORTANT SAFETY INFORMATION INCLUDING THE BOXED WARNING, AND FULL PRESCRIBING INFORMATION at bit.ly/4dl5tuL INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. Trademarks are property of Humacyte Global, Inc © 2026 Humacyte Global Inc. All Rights Reserved.